Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)

Trial Profile

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms AZ11040
  • Most Recent Events

    • 19 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 04 Dec 2017 Planned End Date changed from 1 Jan 2019 to 31 Jan 2020.
    • 04 Dec 2017 Planned primary completion date changed from 1 Jan 2019 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top